glp-1 and kidneys Glucagon-like peptide 1(GLP-1) receptor agonists in the management of the patient with type 2diabetes mellitus chronic kidney disease: an approach for the nephrologist GLP-1 Medications & Their Potential

Understanding the rationale for each medication helps patients engage meaningfully with their treatment plan and recognise when therapeutic goals are being met or when adjustments may be needed

The new BSG & ACPGBI guidance makes it clear: A negative FIT does not rule out GI cancer in IDA Upper GI malignancy risk remains significant Bidirectional endoscopy is still key FIT must not delay investigation in high-risk patients Full guidance in Frontline Gastroenterology: #IDA #FIT #CancerPathways #GIguidelines #FGJournal @British society of gastroenterology @Royal College of Physicians @Oliver Tavabie @benjamin zare @European Society of Gastrointestinal Endoscopy @EASL - The Home of Hepatology @American College of Gastroenterology @American Association for the Study of Liver Diseases (AASLD) @TrevorTabone To view or add a comment, sign in 6,825 followers

However, this study did not use a control group that was well matched to the patients with IIH as BMI of the IIH cohort was significantly higher than that of controls

And even as GLP-1 drugs like Ozempic and Wegovy gain in popularity, scientists all over the world are looking for even more advanced drugs to address diabetes and weight loss